In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Muthukumar KaruppasamyDepartment of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, AL 35294.ORCID 0000-0003-0034-9950 Katherine G EnglishDepartment of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, AL 35294.ORCID 0000-0003-2757-5157 Shelby N RorrerDepartment of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, AL 35294.ORCID 0009-0009-5640-9669 Michael A LopezDepartment of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, AL 35294.ORCID 0000-0002-3029-0761 David K CrossmanDepartment of Genetics at the University of Alabama at Birmingham, Birmingham, AL 35294.ORCID 0000-0002-0981-169X Jodi R PaulDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294.ORCID 0000-0002-5409-5944 Miguel A Monreal-GutierrezDepartment of Physiology and Aging, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0001-8601-4080 Karen L GambleDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294.ORCID 0000-0003-3813-8577 Karyn A EsserDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294.ORCID 0000-0002-5791-1441 Jeffrey J WidrickDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-5597-1141 Matthew S AlexanderDepartment of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children's of Alabama, Birmingham, AL 35294.ORCID 0000-0001-7406-5171 Funding
UAB Pilot Center for Precision Animal Modeling (C-PAM) - Resource and Service SectionU54OD030167 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Elizabeth A Worthey · 2020 to 2026
$15.3MGenetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4MCircadian dysfunction and neurodegenerative diseaseR01NS082413 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAMBLE, KAREN L · 2013 to 2022
$4.6MModulation of Jagged1/Pitpna in DMD as a means of therapyR01AR064300 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI KUNKEL, LOUIS M · 2014 to 2023
$3.9MCircadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawalR01DA046096 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CROPSEY, KAREN L, GAMBLE, KAREN L · 2020 to 2024
$2.8MMuscle clock and weakness: diversity supplementR01AR079220 · NIAMS · UNIVERSITY OF FLORIDA · PI ESSER, KARYN A · 2021 to 2025
$2.8MMuscle clock disruption accelerates the onset and progression of neurodegenerationR01AR066082 · NIAMS · UNIVERSITY OF KENTUCKY · PI ESSER, KARYN A · 2014 to 2018
$2.0MSmad8 is a driver of Duchenne muscular dystrophy pathology via myomiR repressionK08NS120812 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LOPEZ, MICHAEL ALONZO · 2021 to 2025
$1.1MDystrophin as a novel regulator of the circadian clock in skeletal muscle and the brainR21NS140497 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MATTHEW Scott ALEXANDER · 2025 to 2026
$424kNIAMS NIH HHS R01 AR064300NIAMS NIH HHS R01 AR066082NIAMS NIH HHS R01 AR079220NICHD NIH HHS P50 HD105351NIDA NIH HHS R01 DA046096NIH HHS U54 OD030167NINDS NIH HHS K08 NS120812NINDS NIH HHS R01 NS082413NINDS NIH HHS R21 NS140497
6 · The paper itselfAbstract
Duchenne muscular dystrophy (DMD) patients suffer from skeletal and cardiopulmonary weakness, and interestingly up to one third are diagnosed on the autism spectrum. Dystrophin is an essential protein for regulating the transmission of intracellular force to the extracellular matrix within the skeletal muscle, but also plays key roles in neurobehavior and cognitive function. The mouse dystrophin gene (also abbreviated
Indexed as
DMDDystrophinDystrophinopathyMedical Sciencesmuscular dystrophyskeletal muscle
Identifiers
PMID39975305
PMCPMC11838426
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390